SARS-CoV-2および呼吸器ウイルスの炎症性の影響を評価するための適応免疫疾患モデルが新登場。COVID-19、急性呼吸窮迫症候群、ウイルス性肺炎などの臨床疾患に関連する組織免疫反応をモデル化したAdapTive免疫応答モデルを用いて、サイトカイン、ケモカイン、および細胞表面バイオマーカーに対する包括的なレポートを提供します。これらのヒト由来プライアリー細胞を用いたAdapTive免疫応答モデルは、感染症に対する適応免疫応答や慢性炎症反応の評価に活用することができます。
Figure 1. Overview of three available human primary cell-based adaptive immune response models with cell surface receptor, cell health, chemokine, and pro-inflammatory cytokine biomarker readouts relevant for acute and chronic inflammatory biology. AdapT-B models T cell dependent B cell proliferation and activation in secondary lymphoid tissues, AdapT-E models chronic inflammation-driven T cell effector responses in the content of activated vascular endothelium, and AdapT-F models chronic inflammation-driven T cell effector responses in the context of peripheral tissue. Each system is stimulated with a T cell receptor agonist cocktail that includes staphylococcal enterotoxin B (SEB) plus toxic shock syndrome toxin-1 (TSST-1); AdapT-B is also stimulated with anti-IgM antibody.
詳細はウェブページをご参照ください。
サンプルレポートのダウンロードはこちらから☆
Table 1. List of biomarker readouts for each system of the AdapTive Immune Response Series. All systems provide one or more measures of cell health, and measurement of GM-CSF, IFNγ, IL-2, IL-6, IL-17A, TNFα, and MIP-1α. Unique to Eurofins Discovery AdapTive Immune Response Models are cell surface receptor readouts CD69 and E-Selectin in AdapT-E, and VCAM-1 in AdapT-F.
Comprehensive assessment of cytokine, chemokine, cell health, and cell surface biomarkers for therapeutics addressing the consequences of COVID-19, infectious disease, and the chronic inflammatory response. Visit our new webpage to learn more and download a sample report.
According to the Institute for Health Metrics and Evaluation (IHME), the pandemic caused by SARS-CoV-2 is expected to significantly alter the Global Health Burden, a measure of health-related impacts on world economies. Despite the availability of COVID-19 vaccines, long-term disease effects with immune system consequences may be a reality for patients, and clinical trial challenges may persist for biopharma. Human-centric, in vitro assays and physiological models that capture relevant inflammatory and immunomodulatory biology are critical to advance candidate therapeutics to clinical trials.
Our Phenotypic Center of Excellence now offers AdapTive Immune Response Models with lymph, systemic, or tissue environment options that provide uniquely comprehensive reporting on cytokine, chemokine, cell health, and cell surface biomarkers specifically chosen for relevance to COVID-19. These human primary cell-based systems are applicable for understanding the adaptive immune response to infectious disease, as well as chronic inflammatory responses.
ユーロフィンディスカバリー 日本事業部
｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ｡*ﾟ*
★Eurofins Discoveryでは、創薬に役立つ技術・サービスに関するニュースレターを配信しています。配信をご希望の方は下記フォームよりお知らせください。
｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ｡*ﾟ*
